PHOTO ADVISORY -- EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relap

Editors are advised that high-resolution photos are available to accompany the news release, SF07905, EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis, issued earlier today by EMD Serono, Inc.

Caption-a: EMD Serono Logo 1

Caption-b: EMD Serono Logo 2 ... (PRNewsFoto)

Members of the media may download the photos at no charge from the following online archives:

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-a

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b

For more information on the photos, or on gaining access to the archives, media may contact the PR Newswire Photo Desk at [email protected] .

/PRNewswire -- 11/26/2010/

SOURCE EMD Serono, Inc.

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.